share_log

Genesis HealthCare System Builds on Its Investment in BIO-key Biometric Authentication Security as It Migrates to Epic Hyperdrive

Genesis HealthCare System Builds on Its Investment in BIO-key Biometric Authentication Security as It Migrates to Epic Hyperdrive

Genesis Healthcare System在迁移到Epic Hyperdrive时建立了对生物密钥生物识别认证安全的投资
GlobeNewswire ·  2023/12/14 07:58

ZANESVILLE, Ohio and HOLMDEL, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication solutions, announced that its longstanding customer Genesis HealthCare System, the largest healthcare provider in its six-county region of Ohio, will add BIO-key's PortalGuard IAM platform to support its existing BIO-key biometric authentication investment as it migrates to Epic Systems' Hyperdrive end-user application interface. Genesis HealthCare has a network of more than 300 physicians and 4,000 employees across 27 locations.

俄亥俄州赞斯维尔和新泽西州霍尔姆德尔,2023 年 12 月 14 日(GLOBE NEWSWIRE)— Biokey 国际公司(纳斯达克股票代码:BKYI)是一家创新的劳动力和客户身份和访问管理(IAM)提供无密码、无电话和无令牌身份绑定生物识别(IBB)认证解决方案的提供商。该公司宣布,其长期客户Genesis Healthcare System是俄亥俄州六县地区最大的医疗保健提供商,将在迁移时增加Bio-Key的PortalGuard IAM平台,以支持其现有的生物密钥生物识别身份验证投资 Epic Systems 的 Hyperdrive 最终用户应用程序界面Genesis Healthcare在27个地点拥有由300多名医生和4,000名员工组成的网络。

PortalGuard's standards-based integration with Hyperdrive allows Genesis HealthCare System to continue enjoying the security and streamlined biometric authentication user experience that BIO-key provides without re-enrolling employees or adopting more cumbersome and expensive multi-factor authentication solutions.

PortalGuard与Hyperdrive的基于标准的集成使Genesis Healthcare System能够继续享受Bio-Key提供的安全和简化的生物识别身份验证用户体验,而无需重新注册员工,也无需采用更繁琐和更昂贵的多因素身份验证解决方案。

Named by Computerworld as one of the 100 Best Places to Work in IT every year since 2017, Genesis Healthcare utilizes BIO-key biometric software and hardware to secure and streamline its users' login experience for Epic. By deploying PortalGuard IAM, it is able to maintain a consistent user experience and simplify the Hyperdrive migration. PortalGuard fully supports Hyperdrive's modern authentication approach through its SAML Identity Provider (IdP) capabilities. PortalGuard provides seventeen authentication factor options, including WEB-key fingerprint authentication, the same core BIO-key biometric authentication platform regularly used by thousands of Genesis HealthCare employees. Additionally, users can now use PortalGuard for biometric authentication in other hospital applications through its support for standard IdP integration options like SAML, OAUTH, and OpenID Connect.

自2017年以来,Genesis Healthcare被计算机世界评为每年100个最佳IT工作场所之一,它利用Bio-Key生物识别软件和硬件来保护和简化用户对Epic的登录体验。通过部署 PortalGuard IAM,它能够保持一致的用户体验并简化 Hyperdrive 迁移。PortalGuard 通过其 SAML 身份提供商 (IdP) 功能完全支持 Hyperdrive 的现代身份验证方法。PortalGuard提供十七种身份验证要素选项,包括网络密钥指纹身份验证,这是成千上万Genesis Healthcare员工经常使用的核心生物密钥生物识别身份验证平台。此外,通过支持 SAML、OAUTH 和 OpenID Connect 等标准 IdP 集成选项,用户现在可以在其他医院应用程序中使用 PortalGuard 进行生物识别身份验证。

"Epic is a mission-critical application for many of BIO-key's hospital customers, and implementing PortalGuard SAML SSO allows Genesis to maintain streamlined workflows and ensure secure access to patient information with IBB," said Mark Cochran, President of BIO-key – PortalGuard. "Healthcare organizations face the challenge of providing convenient and reliable access to necessary systems while ensuring data privacy and regulatory compliance. BIO-key's Identity-Bound Biometrics allows customers to cost-effectively leverage a phoneless, tokenless, and cardless authentication experience that users prefer because it strikes the proper balance between security and convenience."

Bio-Key——PortalGuard总裁马克·科克伦说:“对于Bio-Key的许多医院客户来说,Epic是一款任务关键型应用程序,实施PortalGuard SAML SSO使Genesis能够保持简化的工作流程,并确保使用IBB安全访问患者信息。“医疗保健组织面临的挑战是提供对必要系统的便捷可靠访问,同时确保数据隐私和监管合规性。Bio-Key的身份绑定生物识别技术使客户能够经济高效地利用用户首选的无电话、无令牌和无卡身份验证体验,因为它在安全性和便利性之间取得了适当的平衡。”

About BIO-key International, Inc. ()
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over thirty-five million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.

关于 Bio-Key 国际有限公司 ()
Bio-Key 利用以生物识别为中心的多因素身份和访问管理 (IAM) 软件,为超过三千五百万用户提供访问保护,从而彻底改变身份验证和网络安全。Bio-Key 允许客户为不同的用例选择正确的身份验证因素,包括无电话、无令牌和无密码的生物识别选项。其托管或内部部署 PortalGuard IAM 解决方案提供经济实惠、易于部署、便捷和安全的计算机、信息、应用程序和高价值交易的访问。

BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy debt repayment obligations and working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.

Bio-key 安全港声明
根据1995年《私人证券诉讼改革法》(“该法”)的定义,本新闻稿中包含的所有陈述均为 “前瞻性陈述”,但历史事实陈述除外。“估计”、“项目”、“打算”、“期望”、“预期”、“相信” 等词语旨在识别前瞻性陈述。此类前瞻性陈述是基于管理层的信念,以及管理层根据该法的 “安全港” 条款做出的假设和管理层目前可以获得的信息。这些陈述不能保证未来的业绩或事件,并且存在风险和不确定性,这些风险和不确定性可能导致实际结果与此类前瞻性陈述中包含或暗示的结果存在重大差异。这些风险和不确定性包括但不限于我们的亏损历史和收入有限;我们筹集额外资金以满足债务偿还义务和营运资金需求的能力;我们继续作为持续经营企业的能力;我们保护知识产权的能力;业务状况的变化;我们的销售策略和产品开发计划的变化;市场的变化;我们执行管理团队的持续服务;安全漏洞;生物识别技术行业的竞争;市场接受度一般的生物识别产品和我们正在开发的产品;我们将销售机会转化为客户合同的能力;我们向亚洲、非洲和其他国外市场扩张的能力;我们将 Swivel Secure 的运营和人员整合到我们的业务中的能力;外币汇率的波动;产品开发的延迟和上述任何内容所依据的假设陈述,以及我们 10-K 表年度报告中标题为 “风险因素” 的其他因素截至十二月三十一日止年度2022 年以及向美国证券交易委员会提交的其他文件。提醒读者不要过分依赖这些前瞻性陈述,这些陈述仅代表截至发表之日。除非法律要求,否则我们没有义务披露对这些前瞻性陈述的任何修订,无论是由于新信息、未来事件还是其他原因。

Engage with BIO-key

使用 Bio-Key 互

Facebook – Corporate:
LinkedIn – Corporate:
Twitter – Corporate: @BIOkeyIntl
Twitter – Investors: @BIO_keyIR
StockTwits: BIO_keyIR
Facebook — 企业:
领英 — 企业:
推特 — 企业: @BIOkeyIntl
推特 — 投资者: @BIO_keyIR
StockTwits: bio_keyir

Investor Contacts

投资者联系方式

William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800

威廉·琼斯,大卫柯林斯
催化剂 IR
BKYI@catalyst-ir.com 或 212-924-9800


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发